Skip to main content
. 2022 Oct 7;101(40):e30871. doi: 10.1097/MD.0000000000030871

Figure 4.

Figure 4.

Changes in tumor size according to mRECIST from pretreatment to during and after the commencement of each previous treatment. a. Lenvatinib. b. Ramucirumab. c. Sorafenib. d. Regorafenib.mRECIST = modified response evaluation criteria in solid tumors.